An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver...
Liver MetastasesColorectal CarcinomaEstimation of the concordance of Tc 99m localization in liver metastases from colorectal carcinoma using SPECT/CT imaging and abdominal FDG (PET)/CT imaging per subject.
Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer
Metastatic Colorectal CancerThis study will be looking at the objective response rate (ORR) as measured by RECIST in in patients with mismatch repair-proficient (MMR-p), advanced colorectal cancer that treated with CY/GVAX in combination with Pembrolizumab.
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
Colorectal CancerMulticenter, multinational, randomized, 3-arm, double-blind, phase II clinical study with 2400mg mesalamine, 1200mg mesalamine or placebo for prevention of colorectal neoplasia in Lynch Syndrome patients for 2 years.
High-activity Natural Killer Immunotherapy for Small Metastases of Colorectal Cancer
Metastatic Colorectal CancerThe aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of colorectal cancer.
Pemetrexed and Erlotinib for Metastatic Colorectal Cancer
Metastatic Colorectal CancerPemetrexed is a multitargeted antifolate, which primarily inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase in the folate-dependent metabolic process. Nowadays, pemetrexed is used to treat malignant pleural mesothelioma and non-squamous non-small cell lung cancer. Preclinical and clinical studies showed that pemetrexed had cytotoxic activity in many kinds of cancers including colorectal cancer. Erlotinib is a tyrosine-kinase inhibitor of EGFR, which was approved for the treatment of non-small cell lung cancer. Erlotinib also showed activity to colorectal cancer cells. Recently, Zhang et al. demonstrated synergistic cytotoxicity of pemetrexed and gefitinib in preclinical study. In this multicenter, non randomized, open label phase II study, investigators aimed to evaluate the efficacy and safety of Pemetrexed and Erlotinib combination.
A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies...
GastroEsophageal CancerColorectal CancerThis is a Phase 1/1b, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of etrumadenant (AB928) in combination with mFOLFOX in participants with advanced metastatic gastroesophageal Cancer (GEC) or colorectal cancer (CRC).
A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant...
Advanced Colorectal CarcinomaA Phase 1 dose escalation study to evaluate APR003 in patients with advanced colorectal cancer (CRC) with malignant liver lesions
Radiomics Assess of Bevacizumab Plus Chemo in Colorectal Cancer Liver Metastases
Colon CancerRectal Cancer1 moreColorectal carcinoma with liver metastasis is one of the major problems bothering physicians worldwide. Bevacizumab combined with chemotherapy is the standard treatment recommended by several guidelines. Despite the high cost, a certain portion of patients couldn't benefit from this therapy. This study is aiming to find out the specific type of patients who would respond to bevacizumab by Radiomics approach, and evaluate the prediction value of this imaging model with clinical and genetic factors.
A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients...
Non-small Cell Lung CancerMetastatic Colorectal Cancer6 moreThis is a prospective, single-arm, open-label, non-interventional, multicenter, post-marketing surveillance to assess the safety and effectiveness of Zirabev(Bevacizumab biosimilar) in domestic patients with non-small cell lung cancer, metastatic colorectal cancer, metastatic breast cancer, advanced or metastatic kidney cancer, cervical cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or glioblastoma multiforme.
Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer
Colorectal Cancer MetastaticThis prospective, multicenter, single arm clinical trial was designed to evaluate the efficacy and safety of Vemurafenib in combination with Irinotecan and Cetuximab in the treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer.